Sparks commentary - IRLAB Therapeutics

Healthcare

Sparks - IRLAB Therapeutics

More on this equity
IRLAB (OMX: IRLAB-A) expands pirepemat IP
Published by Arron Aatkar

IRLAB has been granted a new patent in the US for pirepemat. It covers the salt of the candidate used in ongoing clinical development efforts, and has the potential to extend its protection in this region into the early 2040s. This news is incremental to similar patents, and composition of matter patents, which have already been granted in other key geographies such as Europe, Japan and China (predicted to expire in 2038), fortifying the robust patent portfolio for the candidate.

Pirepemat is currently in a Phase IIb trial, aiming to improve balance and reduce falls in Parkinson’s disease patients. Recruitment should be complete within Q324 and top-line results are anticipated from Q125, after the three-month treatment period, follow-up visits and data analyses.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free